Former Eisai cancer exec joins Gilead

July 10, 2018

Gilead's Kite announced that Michael Amoroso will join the company as senior vice president and head of worldwide commercial, cell therapy. Amoroso will have responsibility for Kite’s commercial organization including sales, marketing, market access and healthcare provider and patient services. Amoroso will begin his new role in August.

Amoroso comes from Eisai where he was senior vice president, Americas commercial for the company’s oncology group. He was responsible for creating and driving commercial strategies for the company’s approved products, pipeline assets and late-stage compounds approaching commercialization. Prior to that, Mr. Amoroso worked at Celgene Corp. for six years in a number of oncology roles.

“Michael brings to the Kite organization significant expertise in the area of oncology and in the commercialization of cancer products,” said Gilead president and CEO John Milligan. “This experience will help us as we seek to build on our existing portfolio, expand our commercial presence in cell therapy in the United States and around the world, and advance new products to market. We are thrilled to welcome Michael to the organization. We believe his leadership and proven track record will help us accelerate our work to bring lifesaving therapies to people with cancer.”

Read the full release